Trading Signals: FOLD Stock Price Prediction and Forecast (Thu. May. 31, 2007 - Fri. Dec. 22, 2023)(Amicus Therapeutics Inc)
| FOLD latest price $13.0600 (0.15%) ($12.8000 - $13.1500) on Fri. Mar. 8, 2019. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 3.81% (three month average) | RSI | 67 | Latest Price | $13.0600(0.15%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | FOLD declines -1.3% a day on average for past five trading days. | Weekly Trend | FOLD advances 7.8% a week on average for past two weeks. | Market Behavior | Normal for large cap. Normal for small cap. | Correlated ETFs | Broad market will support FOLD advance at 0% a week (0% probability) IBB(61%) XBI(57%) IWO(55%) IWM(52%) IWC(50%) | Factors Impacting FOLD price | FOLD will decline at least -1.905% in a week (0% probabilities). TLT(-15%) VXX(-14%) UUP(-13%) VIXM(-9%) IFRA(-8%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.905% (StdDev 3.81%) | Hourly BBV | 0 () | Intraday Trend | 1.5% | | | |
|
5 Day Moving Average | $13.33(-2.03%) | 10 Day Moving Average | $12.99(0.54%) | 20 Day Moving Average | $12.19(7.14%) | To recent high | -6.2% | To recent low | 55.8% | Market Cap | $3.372b | | | | Amicus Therapeutics, Inc. is a biotechnology company focused on discovering, developing, and delivering medicines for people living with rare metabolic diseases. The company is committed to advancing and expanding a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. Amicus Therapeutics has a portfolio of product opportunities including the first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants; a novel, clinical-stage, treatment paradigm for Pompe disease; and a rare disease gene therapy portfolio. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ. |